These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 27815915

  • 21. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
    Teeple A, Muser E.
    J Med Econ; 2019 Dec; 22(12):1268-1273. PubMed ID: 31199173
    [Abstract] [Full Text] [Related]

  • 22. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
    Paul C, van de Kerkhof P, Puig L, Unnebrink K, Goldblum O, Thaçi D.
    Eur J Dermatol; 2012 Dec; 22(6):762-9. PubMed ID: 23178916
    [Abstract] [Full Text] [Related]

  • 23. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.
    J Dermatolog Treat; 2007 Dec; 18(6):341-50. PubMed ID: 18058494
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
    Elewski BE, Okun MM, Papp K, Baker CS, Crowley JJ, Guillet G, Sundaram M, Poulin Y, Gu Y, Geng Z, Williams DA, Rich PA.
    J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
    [Abstract] [Full Text] [Related]

  • 26. An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals.
    Mrowietz U, Kragballe K, Reich K, Griffiths CE, Gu Y, Wang Y, Rozzo SJ.
    Br J Dermatol; 2013 Feb; 168(2):374-80. PubMed ID: 22880843
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA.
    Health Qual Life Outcomes; 2006 Sep 27; 4():71. PubMed ID: 17005043
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
    Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM.
    Br J Dermatol; 2012 Dec 27; 167(6):1374-81. PubMed ID: 22897348
    [Abstract] [Full Text] [Related]

  • 31. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
    Thaçi D, Ortonne JP, Chimenti S, Ghislain PD, Arenberger P, Kragballe K, Saurat JH, Khemis A, Sprøgel P, Esslinger HU, Unnebrink K, Kupper H.
    Br J Dermatol; 2010 Aug 27; 163(2):402-11. PubMed ID: 20377585
    [Abstract] [Full Text] [Related]

  • 32. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab.
    Reich K, Foley P, Han C, McElligott S, Muser E, Li N, Armstrong AW.
    J Dermatolog Treat; 2020 Sep 27; 31(6):617-623. PubMed ID: 31305186
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study.
    Cai L, Gu J, Zheng J, Zheng M, Wang G, Xi LY, Hao F, Liu XM, Sun QN, Wang Y, Lai W, Fang H, Tu YT, Sun Q, Chen J, Gao XH, Gu Y, Teixeira HD, Zhang JZ, Okun MM.
    J Eur Acad Dermatol Venereol; 2017 Jan 27; 31(1):89-95. PubMed ID: 27504914
    [Abstract] [Full Text] [Related]

  • 35. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
    Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM.
    J Eur Acad Dermatol Venereol; 2018 Sep 27; 32(9):1515-1522. PubMed ID: 29512196
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M.
    Dermatology; 2008 Sep 27; 216(3):260-70. PubMed ID: 18187944
    [Abstract] [Full Text] [Related]

  • 38. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.
    Thaçi D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y.
    J Eur Acad Dermatol Venereol; 2015 Feb 27; 29(2):353-360. PubMed ID: 24846518
    [Abstract] [Full Text] [Related]

  • 39. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.
    Faurschou A, Gyldenløve M, Rohde U, Thyssen JP, Zachariae C, Skov L, Knop FK, Vilsbøll T.
    J Eur Acad Dermatol Venereol; 2015 Mar 27; 29(3):555-9. PubMed ID: 25139195
    [Abstract] [Full Text] [Related]

  • 40. Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study.
    Noe MH, Wan MT, Shin DB, Armstrong AW, Duffin KC, Chiesa Fuxench ZC, Kalb RE, Menter A, Simpson EL, Takeshita J, Tyring SK, Van Voorhees AS, Mehta NN, Gelfand JM.
    J Am Acad Dermatol; 2019 Oct 27; 81(4):923-930. PubMed ID: 31163241
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.